Immuno-Oncology
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
WuXi Biologics
PR-M02-19-NI-067Feb 28, 2019
Partnership
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies
WuXi Biologics
PR-M12-18-NI-003Dec 03, 2018
Global Collaboration
ABL Bio and I-Mab Biopharma Announce Global Collaboration on Innovative Bispecific Antibodies
ABL Bio
PR-M08-18-NI-005Aug 01, 2018
Global Collaboration
I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies
I-Mab
PR-M07-18-NI-107Jul 31, 2018